Treatment optimization with secukinumab 150 mg for moderate‐to‐severe psoriasis in clinical practice: a single‐center open‐label 52‐week study
- 16 February 2018
- journal article
- letter
- Published by Wiley in International Journal of Dermatology
- Vol. 57 (5) , 615-617
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patientsJournal of Dermatological Treatment, 2017
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasisJournal of the American Academy of Dermatology, 2016
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010